Aug. 18 at 2:52 PM
$NSPR — Q4 setting up as a catalyst quarter. Two FDA decisions on tap (CGuard Prime 80cm TCAR + original CAS system), plus full run-rate impact of a
$9M cost-cutting plan (~20% headcount reduction) hitting books.
Q2 rev was just
$1.77M after the Prime 135cm recall hit gross margin, but intl revenue +21% YoY offers some offset. Redesigned 135cm heads back to FDA by year-end, US return targeted 1H27.
https://prismmarketview.com/inspiremd-targets-q4-fda-decisions-while-cutting-9-million-in-annual-costs/
